Literature DB >> 16876291

Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer.

David M Lubaroff1, Dev Karan, Michael P Andrews, Anna Acosta, Chadi Abouassaly, Madeva Sharma, Arthur M Krieg.   

Abstract

Immunization with an adenovirus-PSA (Ad5-PSA) vaccine alone strongly induces the expansion of CD8+ T cells with enhanced cytotoxic T lymphocyte (CTL) activity against the antigen-bearing tumor cells in vitro as well as in vivo in a mouse model of prostate cancer. However, in an attempt to enhance the anti-tumor immunity induced by the vaccine, co-administration of CpG oligodeoxynucleotides (CpG ODN) with Ad5-PSA vaccine dramatically reduces the immune responses measured by in vitro CTL activity and the number of IFN-gamma producing cells. Surprisingly, in vivo experiments showed that mice immunized with the combined approach of Ad5-PSA and CpG had enhanced protection against the subsequent tumor challenge as compared to mice immunized with vaccine alone. These data demonstrate an unexpected dichotomous relationship between in vitro CTL activity and in vivo tumor protection suggesting that an alternative mechanism of tumor destruction was invoked after co-administration of the CpG ODN with the vaccine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16876291     DOI: 10.1016/j.vaccine.2006.04.022

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  Cancer immunotherapy: a paradigm shift for prostate cancer treatment.

Authors:  Dev Karan; Jeffrey M Holzbeierlein; Peter Van Veldhuizen; J Brantley Thrasher
Journal:  Nat Rev Urol       Date:  2012-05-29       Impact factor: 14.432

Review 2.  Development of TLR9 agonists for cancer therapy.

Authors:  Arthur M Krieg
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

3.  Vaccine immunotherapy for prostate cancer: from mice to men.

Authors:  David M Lubaroff; Daniel Vaena; James A Brown; Pamela Zehr; Karen C Griffith; Erica Brown; Julie Eastman; Kenneth Nepple; Ambika Kattula; Richard D Williams
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

4.  Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.

Authors:  Dev Karan
Journal:  Vaccine       Date:  2017-09-20       Impact factor: 3.641

5.  Chitosan is a surprising negative modulator of cytotoxic CD8+ T cell responses elicited by adenovirus cancer vaccines.

Authors:  Caitlin D Lemke; Jessica B Graham; Sean M Geary; Gideon Zamba; David M Lubaroff; Aliasger K Salem
Journal:  Mol Pharm       Date:  2011-08-09       Impact factor: 4.939

6.  Formulation and evaluation of oral microparticulate ovarian cancer vaccines.

Authors:  Suprita A Tawde; Lipika Chablani; Archana Akalkotkar; Cherilyn D'Souza; Maurizio Chiriva-Internati; Periasamy Selvaraj; Martin J D'Souza
Journal:  Vaccine       Date:  2012-06-28       Impact factor: 3.641

Review 7.  Innovative strategies for co-delivering antigens and CpG oligonucleotides.

Authors:  Yogita Krishnamachari; Aliasger K Salem
Journal:  Adv Drug Deliv Rev       Date:  2009-01-19       Impact factor: 15.470

8.  Antigen-coated poly α-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations.

Authors:  Caitlin D Lemke; Sean M Geary; Vijaya B Joshi; Aliasger K Salem
Journal:  Biomaterials       Date:  2013-01-11       Impact factor: 12.479

Review 9.  Proposed mechanisms of action for prostate cancer vaccines.

Authors:  Sean M Geary; Caitlin D Lemke; David M Lubaroff; Aliasger K Salem
Journal:  Nat Rev Urol       Date:  2013-02-12       Impact factor: 14.432

10.  CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies.

Authors:  Aliasger K Salem; George J Weiner
Journal:  Adv Drug Deliv Rev       Date:  2009-01-07       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.